{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:55:43Z","timestamp":1791093343738,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1038\/leu.2013.151","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T06:39:04Z","timestamp":1368513544000},"page":"1996-2005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target"],"prefix":"10.1038","volume":"27","author":[{"given":"J G","family":"Harb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Neviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B J","family":"Chyla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J","family":"Ferenchak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Oaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hokland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D C","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Caligiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C S","family":"Huettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Perrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,14]]},"reference":[{"key":"BFleu2013151_CR1","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","volume":"120","author":"J Cortes","year":"2012","unstructured":"Cortes J, Kantarjian H . How I treat newly diagnosed chronic phase CML. Blood 2012; 120: 1390\u20131397.","journal-title":"Blood"},{"key":"BFleu2013151_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R . How I treat CML blast crisis. Blood 2012; 120: 737\u2013747.","journal-title":"Blood"},{"key":"BFleu2013151_CR3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/leu.2010.71","volume":"24","author":"A Hochhaus","year":"2010","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (vol 23, pg 1054, 2009). Leukemia 2010; 24: 1102\u20131102.","journal-title":"Leukemia"},{"key":"BFleu2013151_CR4","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254\u20132264.","journal-title":"J Clin Invest"},{"key":"BFleu2013151_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J . Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619\u20131630.","journal-title":"Blood"},{"key":"BFleu2013151_CR6","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1182\/blood-2011-10-383000","volume":"119","author":"D Milojkovic","year":"2012","unstructured":"Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M et al. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 2012; 119: 1838\u20131843.","journal-title":"Blood"},{"key":"BFleu2013151_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1586\/era.12.10","volume":"12","author":"M Karvela","year":"2012","unstructured":"Karvela M, Helgason GV, Holyoake TL . Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Rev Anticancer Ther 2012; 12: 381\u2013392.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFleu2013151_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G . Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615\u2013619.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2013151_CR9","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","volume":"7","author":"NN Bewry","year":"2008","unstructured":"Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA . Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169\u20133175.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2013151_CR10","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/leu.2011.325","volume":"26","author":"E Traer","year":"2012","unstructured":"Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 2012; 26: 1140\u20131143.","journal-title":"Leukemia"},{"key":"BFleu2013151_CR11","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1073\/pnas.92.12.5287","volume":"92","author":"I Sanchez-Garcia","year":"1995","unstructured":"Sanchez-Garcia I, Grutz G . Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995; 92: 5287\u20135291.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2013151_CR12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","volume":"16","author":"GP Amarante-Mendes","year":"1998","unstructured":"Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DEH, Witte ON, Green DR . Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-x(L). Oncogene 1998; 16: 1383\u20131390.","journal-title":"Oncogene"},{"key":"BFleu2013151_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","volume":"191","author":"M Horita","year":"2000","unstructured":"Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-(XL). J Exp Med 2000; 191: 977\u2013984.","journal-title":"J Exp Med"},{"key":"BFleu2013151_CR14","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","volume":"105","author":"KJ Aichberger","year":"2005","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303\u20133311.","journal-title":"Blood"},{"key":"BFleu2013151_CR15","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/leu.2012.19","volume":"26","author":"AR Soliera","year":"2012","unstructured":"Soliera AR, Mariani SA, Audia A, Lidonnici MR, Addya S, Ferrari-Amorotti G et al. Gfi-1 inhibits proliferation and colony formation of p210BCR\/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia 2012; 26: 1555\u20131563.","journal-title":"Leukemia"},{"key":"BFleu2013151_CR16","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/leu.2011.55","volume":"25","author":"EK Allan","year":"2011","unstructured":"Allan EK, Holyoake TL, Craig AR, Jorgensen HG . Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells. Leukemia 2011; 25: 985\u2013994.","journal-title":"Leukemia"},{"key":"BFleu2013151_CR17","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2009.52","volume":"23","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S . Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009; 23: 1446\u20131454.","journal-title":"Leukemia"},{"key":"BFleu2013151_CR18","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/carcin\/bgq062","volume":"31","author":"I Gonzalez-Herrero","year":"2010","unstructured":"Gonzalez-Herrero I, Vicente-Duenas C, Orfao A, Flores T, Jimenez R, Cobaleda C et al. Bcl2 is not required for the development and maintenance of leukemia stem cells in mice. Carcinogenesis 2010; 31: 1292\u20131297.","journal-title":"Carcinogenesis"},{"key":"BFleu2013151_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1126\/science.1106114","volume":"307","author":"JT Opferman","year":"2005","unstructured":"Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307: 1101\u20131104.","journal-title":"Science"},{"key":"BFleu2013151_CR20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","volume":"140","author":"J Kuroda","year":"2008","unstructured":"Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 2008; 140: 181\u2013190.","journal-title":"Br J Haematol"},{"key":"BFleu2013151_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1124\/mol.109.060780","volume":"77","author":"LM High","year":"2010","unstructured":"High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2010; 77: 483\u2013494.","journal-title":"Mol Pharmacol"},{"key":"BFleu2013151_CR22","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2007-08-108803","volume":"111","author":"JG Harb","year":"2008","unstructured":"Harb JG, Chyla BI, Huettner CS . Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood 2008; 111: 3760\u20133769.","journal-title":"Blood"},{"key":"BFleu2013151_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/leu.2011.285","volume":"26","author":"DH Mak","year":"2012","unstructured":"Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H et al. Activation of apoptosis signaling eliminates CD34(+) progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2012; 26: 788\u2013794.","journal-title":"Leukemia"},{"key":"BFleu2013151_CR24","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J . Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 7519\u20137527.","journal-title":"Clin Cancer Res"},{"key":"BFleu2013151_CR25","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421\u20133428.","journal-title":"Cancer Res"},{"key":"BFleu2013151_CR26","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1073\/pnas.0606176103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DCS et al. Bim and Bad mediate imatinib-induced killing of Bcr\/Abl(+) leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907\u201314912.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2013151_CR27","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood.V96.2.676","volume":"96","author":"P Salomoni","year":"2000","unstructured":"Salomoni P, Condorelli F, Sweeney SM, Calabretta B . Versatility of BCR\/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 2000; 96: 676\u2013684.","journal-title":"Blood"},{"key":"BFleu2013151_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/MCB.20.4.1179-1186.2000","volume":"20","author":"MS Neshat","year":"2000","unstructured":"Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL . The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000; 20: 1179\u20131186.","journal-title":"Mol Cell Biol"},{"key":"BFleu2013151_CR29","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1038\/onc.2009.44","volume":"27","author":"NN Danial","year":"2008","unstructured":"Danial NN . BAD: undertaker by night, candyman by day. Oncogene 2008; 27: S53\u2013S70.","journal-title":"Oncogene"},{"key":"BFleu2013151_CR30","first-page":"5716","volume":"63","author":"C Ly","year":"2003","unstructured":"Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST . Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63: 5716\u20135722.","journal-title":"Cancer Res"},{"key":"BFleu2013151_CR31","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski T, Bellacosa A, NieborowskaSkorska M, Majewski M, Martinez R, Choi JK et al. Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway. EMBO J 1997; 16: 6151\u20136161.","journal-title":"EMBO J"},{"key":"BFleu2013151_CR32","first-page":"638","volume":"11","author":"SV Bhagwat","year":"2010","unstructured":"Bhagwat SV, Crew AP . Novel inhibitors of mTORC1 and mTORC2. Curr Opin Investig Drugs 2010; 11: 638\u2013645.","journal-title":"Curr Opin Investig Drugs"},{"key":"BFleu2013151_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1371\/journal.pbio.1000038","volume":"7","author":"ME Feldman","year":"2009","unstructured":"Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Plos Biol 2009; 7: 371\u2013383.","journal-title":"Plos Biol"},{"key":"BFleu2013151_CR34","doi-asserted-by":"publisher","first-page":"12469","DOI":"10.1073\/pnas.1005114107","volume":"107","author":"N Carayol","year":"2010","unstructured":"Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H et al. Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010; 107: 12469\u201312474.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2013151_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nm.2091","volume":"16","author":"MR Janes","year":"2010","unstructured":"Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA et al. Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor. Nat Med 2010; 16: 205\u2013U115.","journal-title":"Nat Med"},{"key":"BFleu2013151_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","volume":"105","author":"S Koschmieder","year":"2005","unstructured":"Koschmieder S, Gottgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105: 324\u2013334.","journal-title":"Blood"},{"key":"BFleu2013151_CR37","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1128\/MCB.22.7.2255-2266.2002","volume":"22","author":"A Iervolino","year":"2002","unstructured":"Iervolino A, Santilli G, Trotta R, Guerzoni C, Cesi V, Bergamaschi A et al. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR\/ABL leukemogenesis. Mol Cell Biol 2002; 22: 2255\u20132266.","journal-title":"Mol Cell Biol"},{"key":"BFleu2013151_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/71691","volume":"24","author":"CS Huettner","year":"2000","unstructured":"Huettner CS, Zhang P, Van Etten RA, Tenen DG . Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57\u201360.","journal-title":"Nat Genet"},{"key":"BFleu2013151_CR39","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1182\/blood-2002-02-0355","volume":"100","author":"HS Radomska","year":"2002","unstructured":"Radomska HS, Gonzalez DA, Okuno Y, Iwasaki H, Nagy A, Akashi K et al. Transgenic targeting with regulatory elements of the human CD34 gene. Blood 2002; 100: 4410\u20134419.","journal-title":"Blood"},{"key":"BFleu2013151_CR40","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1242\/dev.127.22.4949","volume":"127","author":"KU Wagner","year":"2000","unstructured":"Wagner KU, Claudio E, Rucker EB, Riedlinger G, Broussard C, Schwartzberg PL et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000; 127: 4949\u20134958.","journal-title":"Development"},{"key":"BFleu2013151_CR41","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1046\/j.1365-2141.2003.04217.x","volume":"120","author":"K Mihara","year":"2003","unstructured":"Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 2003; 120: 846\u2013849.","journal-title":"Br J Haematol"},{"key":"BFleu2013151_CR42","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1172\/JCI31494","volume":"117","author":"IM Berquin","year":"2007","unstructured":"Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM et al. Modulation of prostate cancer genetic risk by ornega-3 and ornega-6 fatty acids. J Clin Invest 2007; 117: 1866\u20131875.","journal-title":"J Clin Invest"},{"key":"BFleu2013151_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ng791","volume":"30","author":"D Perrotti","year":"2002","unstructured":"Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. BCR-ABL suppresses C\/EBP alpha expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48\u201358.","journal-title":"Nat Genet"},{"key":"BFleu2013151_CR44","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","volume":"107","author":"M Notari","year":"2006","unstructured":"Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A et al. A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006; 107: 2507\u20132516.","journal-title":"Blood"},{"key":"BFleu2013151_CR45","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1182\/blood.V97.5.1289","volume":"97","author":"CW Chiang","year":"2001","unstructured":"Chiang CW, Harris G, Ellig C, Masters SC, Subramanian R, Shenolikar S et al. Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin-3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation. Blood 2001; 97: 1289\u20131297.","journal-title":"Blood"},{"key":"BFleu2013151_CR46","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood.V96.12.3915","volume":"96","author":"M Cirinna","year":"2000","unstructured":"Cirinna M, Trotta R, Salomoni P, Kossev P, Wasik M, Perrotti D et al. Bcl-2 expression restores the leukemogenic potential of a BCR\/ABL mutant defective in transformation. Blood 2000; 96: 3915\u20133921.","journal-title":"Blood"},{"key":"BFleu2013151_CR47","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.1038\/sj.onc.1203076","volume":"18","author":"XJ Fang","year":"1999","unstructured":"Fang XJ, Yu SX, Eder A, Mao ML, Bast RC, Boyd D et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999; 18: 6635\u20136640.","journal-title":"Oncogene"},{"key":"BFleu2013151_CR48","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFleu2013151_CR49","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CHM Jamieson","year":"2004","unstructured":"Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657\u2013667.","journal-title":"N Engl J Med"},{"key":"BFleu2013151_CR50","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1182\/blood-2007-05-090472","volume":"111","author":"AM Eiring","year":"2008","unstructured":"Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M et al. Identification of novel posttranscriptional targets of the BCR\/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR\/ABL leukemogenesis. Blood 2008; 111: 816\u2013828.","journal-title":"Blood"},{"key":"BFleu2013151_CR51","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D . The biology of CML blast crisis. Blood 2004; 103: 4010\u20134022.","journal-title":"Blood"},{"key":"BFleu2013151_CR52","doi-asserted-by":"publisher","first-page":"10002","DOI":"10.1073\/pnas.1633833100","volume":"100","author":"S Jaiswal","year":"2003","unstructured":"Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL . Expression of BCR\/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci USA 2003; 100: 10002\u201310007.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2013151_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/1097-0142(20010101)91:1<9::AID-CNCR2>3.0.CO;2-E","volume":"91","author":"FM Ravandi","year":"2001","unstructured":"Ravandi FM, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ et al. Expression of apoptosis proteins in chronic myelogenous leukemia. Cancer 2001; 91: 9.","journal-title":"Cancer"},{"key":"BFleu2013151_CR54","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/leu.2011.20","volume":"25","author":"C Evangelisti","year":"2011","unstructured":"Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 781\u2013791.","journal-title":"Leukemia"},{"key":"BFleu2013151_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/1541-7786.MCR-11-0394","volume":"10","author":"LC Spender","year":"2012","unstructured":"Spender LC, Inman GJ . Phosphoinositide 3-kinase\/AKT\/mTORC1\/2 Signaling Determines Sensitivity of Burkitt's Lymphoma Cells to BH3 mimetics. Mol Cancer Res 2012; 10: 347\u2013359.","journal-title":"Mol Cancer Res"},{"key":"BFleu2013151_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","volume":"40","author":"K Airiau","year":"2012","unstructured":"Airiau K, Mahon F-X, Josselin M, Jeanneteau M, Turcq B, Belloc F . ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Exp Hematol 2012; 40: 367\u2013378.","journal-title":"Exp Hematol"},{"key":"BFleu2013151_CR57","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1182\/blood-2011-12-400929","volume":"119","author":"D Merino","year":"2012","unstructured":"Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807\u20135816.","journal-title":"Blood"},{"key":"BFleu2013151_CR58","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1182\/blood-2011-11-393934","volume":"120","author":"Z Zeng","year":"2012","unstructured":"Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA et al. Targeting of mTORC1\/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012; 120: 2679\u20132689.","journal-title":"Blood"},{"key":"BFleu2013151_CR59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T, Samudio I, Ruvalo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375\u2013388.","journal-title":"Cancer Cell"},{"key":"BFleu2013151_CR60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389\u2013399.","journal-title":"Cancer Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2013151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013151","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:04:36Z","timestamp":1715360676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,14]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["BFleu2013151"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.151","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,14]]},"assertion":[{"value":"14 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}